Cause-specific hazards of relapse
| . | Patients, N/tested (SCT patients) . | SCT censoring . | No SCT censoring . | ||
|---|---|---|---|---|---|
| Cause-specific HR (95% CI) . | P value . | Cause-specific HR (95% CI) . | P value . | ||
| Univariable analysis | |||||
| BCP-ALL | |||||
| WBC ≥30 × 109/L* | 67/260 (39/107) | 1.85 (1.01-3.38) | .046 | 1.90 (1.19-3.02) | .007 |
| CNS involvement* | 15/257 (9/107) | 1.41 (0.44-4.56) | .56 | 0.87 (0.32-2.40) | .79 |
| CD10-negative immature ALL* | 67/250 (38/102) | 0.90 (0.45-1.79) | .76 | 0.75 (0.43-1.29) | .29 |
| MLL gene rearrangement (t[4;11] or other)* | 29/253 (18/105) | 2.11 (0.94-4.73) | .07 | 1.50 (0.79-2.85) | .22 |
| t(1;19)* | 14/244 (9/103) | 1.15 (0.28-4.76) | .85 | 1.04 (0.38-2.84) | .95 |
| Low hypodiploidy/near triploidy* | 11/230 (5/100) | 1.43 (0.44-4.60) | .55 | 1.23 (0.45-3.37) | .69 |
| Complex karyotype* | 18/258 (5/107) | 1.04 (0.75-1.44) | .83 | 1.01 (0.76-1.36) | .92 |
| IKZF1 gene deletion | 54/216 (20/88) | 2.65 (1.48-4.73) | .001 | 2.06 (1.25-3.39) | .004 |
| MRD1 level ≥10−4 | 111/260 (59/107) | 3.45 (2.00-6.00) | <.001 | 3.07 (1.92-4.90) | <.001 |
| T-ALL | |||||
| WBC ≥100 × 109/L | 37/163 (13/51) | 1.65 (0.82-3.33) | .16 | 1.77 (0.98-3.21) | .06 |
| CNS involvement* | 18/162 (14/51) | 2.83 (0.82-9.72) | .10 | 1.89 (0.89-4.04) | .10 |
| Pro-T/mature-T ALL | 22/151 (9/47) | 1.34 (0.52-3.47) | .55 | 1.93 (0.95-3.90) | .07 |
| Complex karyotype* | 14/161 (8/51) | 0.86 (0.54-1.35) | .51 | 0.82 (0.54-1.24) | .34 |
| TLX1 overexpression | 29/127 (5/43) | 0.92 (0.41-2.10) | .85 | 0.77 (0.35-1.67) | .51 |
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics | 60/125 (20/39) | 5.33 (2.14-13.26) | <.001 | 4.70 (2.14-10.32) | <.001 |
| MRD1 level ≥10−4 | 47/163 (25/51) | 2.93 (1.50-5.71) | .002 | 2.50 (1.44-4.37) | .001 |
| Multivariable analysis | |||||
| BCP-ALL | |||||
| MRD1 level ≥10−4 | — | 3.21 (1.67-6.18) | <.001 | 2.49 (1.43-4.32) | .001 |
| IKZF1 gene deletion | — | 2.43 (1.29-4.60) | .006 | 1.75 (1.0-3.05) | .05 |
| MLL gene rearrangement (t[4;11] or other)* | — | 3.15 (1.13-8.80) | .028 | 1.73 (0.79-3.77) | .17 |
| WBC ≥30 × 109/L* | — | 1.01 (0.46-2.24) | .98 | 1.37 (0.76-2.47) | .30 |
| T-ALL | |||||
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics | — | 5.59 (1.82-17.19) | .003 | 4.39 (1.75-11.03) | .002 |
| MRD1 level ≥10−4 | — | 2.50 (1.06-5.87) | .036 | 3.13 (1.51-6.50) | .002 |
| WBC ≥100 × 109/L | — | 1.34 (0.54-3.35) | .53 | 1.51 (0.70-3.26) | .29 |
| CNS involvement* | — | 2.49 (0.47-13.3) | .29 | 1.38 (0.51-3.74) | .53 |
| Pro-T/mature-T ALL | — | 1.01 (0.33-3.09) | .98 | 1.22 (0.53-2.80) | .63 |
| . | Patients, N/tested (SCT patients) . | SCT censoring . | No SCT censoring . | ||
|---|---|---|---|---|---|
| Cause-specific HR (95% CI) . | P value . | Cause-specific HR (95% CI) . | P value . | ||
| Univariable analysis | |||||
| BCP-ALL | |||||
| WBC ≥30 × 109/L* | 67/260 (39/107) | 1.85 (1.01-3.38) | .046 | 1.90 (1.19-3.02) | .007 |
| CNS involvement* | 15/257 (9/107) | 1.41 (0.44-4.56) | .56 | 0.87 (0.32-2.40) | .79 |
| CD10-negative immature ALL* | 67/250 (38/102) | 0.90 (0.45-1.79) | .76 | 0.75 (0.43-1.29) | .29 |
| MLL gene rearrangement (t[4;11] or other)* | 29/253 (18/105) | 2.11 (0.94-4.73) | .07 | 1.50 (0.79-2.85) | .22 |
| t(1;19)* | 14/244 (9/103) | 1.15 (0.28-4.76) | .85 | 1.04 (0.38-2.84) | .95 |
| Low hypodiploidy/near triploidy* | 11/230 (5/100) | 1.43 (0.44-4.60) | .55 | 1.23 (0.45-3.37) | .69 |
| Complex karyotype* | 18/258 (5/107) | 1.04 (0.75-1.44) | .83 | 1.01 (0.76-1.36) | .92 |
| IKZF1 gene deletion | 54/216 (20/88) | 2.65 (1.48-4.73) | .001 | 2.06 (1.25-3.39) | .004 |
| MRD1 level ≥10−4 | 111/260 (59/107) | 3.45 (2.00-6.00) | <.001 | 3.07 (1.92-4.90) | <.001 |
| T-ALL | |||||
| WBC ≥100 × 109/L | 37/163 (13/51) | 1.65 (0.82-3.33) | .16 | 1.77 (0.98-3.21) | .06 |
| CNS involvement* | 18/162 (14/51) | 2.83 (0.82-9.72) | .10 | 1.89 (0.89-4.04) | .10 |
| Pro-T/mature-T ALL | 22/151 (9/47) | 1.34 (0.52-3.47) | .55 | 1.93 (0.95-3.90) | .07 |
| Complex karyotype* | 14/161 (8/51) | 0.86 (0.54-1.35) | .51 | 0.82 (0.54-1.24) | .34 |
| TLX1 overexpression | 29/127 (5/43) | 0.92 (0.41-2.10) | .85 | 0.77 (0.35-1.67) | .51 |
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics | 60/125 (20/39) | 5.33 (2.14-13.26) | <.001 | 4.70 (2.14-10.32) | <.001 |
| MRD1 level ≥10−4 | 47/163 (25/51) | 2.93 (1.50-5.71) | .002 | 2.50 (1.44-4.37) | .001 |
| Multivariable analysis | |||||
| BCP-ALL | |||||
| MRD1 level ≥10−4 | — | 3.21 (1.67-6.18) | <.001 | 2.49 (1.43-4.32) | .001 |
| IKZF1 gene deletion | — | 2.43 (1.29-4.60) | .006 | 1.75 (1.0-3.05) | .05 |
| MLL gene rearrangement (t[4;11] or other)* | — | 3.15 (1.13-8.80) | .028 | 1.73 (0.79-3.77) | .17 |
| WBC ≥30 × 109/L* | — | 1.01 (0.46-2.24) | .98 | 1.37 (0.76-2.47) | .30 |
| T-ALL | |||||
| High-risk NOTCH1/FBXW7/RAS/PTEN genetics | — | 5.59 (1.82-17.19) | .003 | 4.39 (1.75-11.03) | .002 |
| MRD1 level ≥10−4 | — | 2.50 (1.06-5.87) | .036 | 3.13 (1.51-6.50) | .002 |
| WBC ≥100 × 109/L | — | 1.34 (0.54-3.35) | .53 | 1.51 (0.70-3.26) | .29 |
| CNS involvement* | — | 2.49 (0.47-13.3) | .29 | 1.38 (0.51-3.74) | .53 |
| Pro-T/mature-T ALL | — | 1.01 (0.33-3.09) | .98 | 1.22 (0.53-2.80) | .63 |
The end point was CIR, after censoring patients who received allogeneic SCT in first CR or not, in BCP-ALL and T-ALL subsets separately.
Univariable and multivariable cause-specific HRs and P values are given;
Risk factors used in GRAALL trials.